Longevity
FDA proposes easing approval rules for cancer-diagnostic lab tests
By Life and Health Today Staff, . Life and Health Today.
What the FDA is proposing
Pathologists who want to know whether a tumor is likely to respond to a specific cancer drug often rely on a test called immunohistochemistry, or IHC. The technique uses antibodies to stain tissue samples, making particular proteins visible under a microscope. When a drug's approval depends on patients first testing positive for one of those proteins, the accompanying IHC test is called a companion diagnostic.
The Food and Drug Administration published a proposed rule in the Federal Register on November 12, 2026, that would move a defined group of these companion IHC test systems from Class III to Class II device status. In the FDA's three-tier framework for medical devices, Class III carries the heaviest regulatory burden: manufacturers must go through premarket approval, a process that requires clinical evidence of safety and effectiveness before a product can be sold. Class II devices instead go through premarket notification, a shorter review in which a manufacturer demonstrates that a new device is substantially equivalent to one already on the market.
The proposal covers twelve product codes that the agency uses to catalog IHC systems tied to approved oncology drugs. The FDA said it also intends to introduce specific "special controls," meaning targeted requirements such as performance standards and labeling rules, that it believes are sufficient to assure safety and effectiveness at the lower classification level.
Why the distinction matters
For a reader deciding whether this affects them, the practical question is what it means for the tests their oncologist orders. Companion diagnostics are already in clinical use; the proposal does not change whether they exist or whether insurers cover them. What it changes is the regulatory pathway a manufacturer must follow to bring a new version of such a test to market.
A National Institutes of Health review published in PMC noted that the FDA had signaled it anticipated most existing Class III in vitro diagnostics, the broad category that includes IHC tests, would eventually be reclassified downward. The proposed rule is consistent with that direction.
The lighter pathway could, in principle, make it easier and faster for manufacturers to develop new companion tests as new cancer drugs are approved. Whether that translates into faster access for patients or lower costs is not established by the proposal itself.
What the proposal does not settle
The rule is a proposal, not a final decision. The FDA is accepting public comment, and the classification could be modified or withdrawn before it takes effect. The agency has not published a timeline for finalizing the rule in the materials available.
The proposal also does not address laboratory-developed tests, which are IHC assays that individual hospital labs design and run in-house rather than purchasing as a commercial kit. Those tests operate under a separate and still-evolving regulatory framework that the PMC review described as distinct from the device classification system at issue here.
For patients, the relevant question is whether the specific companion diagnostic their oncologist uses is validated for the drug being considered. That is a clinical conversation, not one this regulatory change resolves on its own.
Life & Health Today provides information for educational purposes only, not medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional.